Comprehensive Stock Comparison
Compare XOMA Corporation (XOMAP) vs Vertex Pharmaceuticals Incorporated (VRTX) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth |  XOMAP | 498.7% revenue growth vs VRTX's 8.9% |
| Value |  VRTX | Lower P/E (24.7x vs 38.7x) |
| Quality / Margins | XOMAP | 46.1% net margin vs VRTX's 31.3% |
| Stability / Safety | XOMAP | Beta 0.13 vs VRTX's 0.44 |
| Dividends | XOMAP | 1.8% yield; VRTX pays no meaningful dividend |
| Momentum (1Y) | XOMAP | +8.7% vs VRTX's -2.8% |
| Efficiency (ROA) | VRTX | 14.8% ROA vs XOMAP's 8.3%, ROIC 22.8% vs -37.6% |
Who Each Stock Is For
Income & stability
XOMAPDividend streak 0 yrs, beta 0.13, yield 1.8%
Growth exposure
XOMAPRev growth 498.7%, EPS growth 59.2%, 3Y rev CAGR -9.3%
Long-term compounding (10Y)
VRTX425.4% 10Y total return vs XOMAP's 50.5%
Sleep-well-at-night portfolio
XOMAPLower volatility, beta 0.13, current ratio 5.15x
Defensive / Recession hedge
XOMAPBeta 0.13, yield 1.8%, current ratio 5.15x
Business Model
What each company does and how it makes money
XOMA Corporation is a biotechnology royalty aggregator that acquires future economic rights to pre-commercial therapeutic candidates licensed to pharmaceutical partners. It generates revenue primarily through milestone payments and royalties from its portfolio of approximately 70 early to mid-stage clinical assets — with no single asset dominating its income stream. The company's moat lies in its specialized expertise in evaluating and structuring royalty agreements for complex biotech assets, creating a diversified portfolio of potential future revenue streams.
Vertex Pharmaceuticals is a biotechnology company focused on developing and commercializing transformative medicines for serious diseases, with its flagship franchise targeting cystic fibrosis. It generates nearly all its revenue from CF therapies — primarily Trikafta/Kaftrio — while building a pipeline in pain, kidney disease, and type 1 diabetes. Its moat stems from deep scientific expertise in CFTR biology and a dominant, near-monopoly position in the CF treatment market.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
VRTX 2XOMAP 1XOMAP4/6 metricsVRTX7/9 metricsVRTX5/6 metricsVRTX leads in 2 of 6 categories (Profitability & Efficiency, Total Returns). XOMAP leads in 1 (Financial Metrics). 2 tied.
Financial Metrics (TTM)
VRTX is the larger business by revenue, generating $11.7B annually — 248.9x XOMAP's $47M. XOMAP is the more profitable business, keeping 46.1% of every revenue dollar as net income compared to VRTX's 31.3%. On growth, XOMAP holds the edge at +29.9% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | XOMAPXOMA Corporation | VRTXVertex Pharmaceut… |
|---|---|---|
| RevenueTrailing 12 months | $47M | $11.7B |
| EBITDAEarnings before interest/tax | $13M | $4.2B |
| Net IncomeAfter-tax profit | $22M | $3.7B |
| Free Cash FlowCash after capex | $5M | $3.3B |
| Gross MarginGross profit ÷ Revenue | +93.6% | +86.3% |
| Operating MarginEBIT ÷ Revenue | -15.0% | +34.1% |
| Net MarginNet income ÷ Revenue | +46.1% | +31.3% |
| FCF MarginFCF ÷ Revenue | +11.4% | +28.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | +29.9% | +11.0% |
| EPS Growth (YoY)Latest quarter vs prior year | +144.0% | +4.7% |
Valuation Metrics
| Metric | XOMAPXOMA Corporation | VRTXVertex Pharmaceut… |
|---|---|---|
| Market CapShares × price | $317M | $121.4B |
| Enterprise ValueMkt cap + debt − cash | $335M | $120.0B |
| Trailing P/EPrice ÷ TTM EPS | -15.62x | 31.19x |
| Forward P/EPrice ÷ next-FY EPS est. | 38.69x | 24.68x |
| PEG RatioP/E ÷ EPS growth rate | — | 3.77x |
| EV / EBITDAEnterprise value multiple | — | 25.60x |
| Price / SalesMarket cap ÷ Revenue | 11.14x | 10.11x |
| Price / BookPrice ÷ Book value/share | 3.68x | 6.61x |
| Price / FCFMarket cap ÷ FCF | — | 38.01x |
Profitability & Efficiency
VRTX delivers a 21.2% return on equity — every $100 of shareholder capital generates $21 in annual profit, vs $20 for XOMAP. VRTX carries lower financial leverage with a 0.20x debt-to-equity ratio, signaling a more conservative balance sheet compared to XOMAP's 1.46x. On the Piotroski fundamental quality scale (0–9), VRTX scores 5/9 vs XOMAP's 4/9, reflecting solid financial health.
| Metric | XOMAPXOMA Corporation | VRTXVertex Pharmaceut… |
|---|---|---|
| ROE (TTM)Return on equity | +20.1% | +21.2% |
| ROA (TTM)Return on assets | +8.3% | +14.8% |
| ROICReturn on invested capital | -37.6% | +22.8% |
| ROCEReturn on capital employed | -19.4% | +23.0% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 5 |
| Debt / EquityFinancial leverage | 1.46x | 0.20x |
| Net DebtTotal debt minus cash | $18M | $3.7B |
| Cash & Equiv.Liquid assets | $102M | $5.1B |
| Total DebtShort + long-term debt | $119M | $3.7B |
| Interest CoverageEBIT ÷ Interest expense | 2.20x | 348.55x |
Total Returns (with DRIP)
A $10,000 investment in VRTX five years ago would be worth $22,544 today (with dividends reinvested), compared to $14,590 for XOMAP. Over the past 12 months, XOMAP leads with a +8.7% total return vs VRTX's -2.8%. The 3-year compound annual growth rate (CAGR) favors VRTX at 17.9% vs XOMAP's 8.9% — a key indicator of consistent wealth creation.
| Metric | XOMAPXOMA Corporation | VRTXVertex Pharmaceut… |
|---|---|---|
| YTD ReturnYear-to-date | -3.0% | +5.7% |
| 1-Year ReturnPast 12 months | +8.7% | -2.8% |
| 3-Year ReturnCumulative with dividends | +29.1% | +63.9% |
| 5-Year ReturnCumulative with dividends | +45.9% | +125.4% |
| 10-Year ReturnCumulative with dividends | +50.5% | +425.4% |
| CAGR (3Y)Annualised 3-year return | +8.9% | +17.9% |
Risk & Volatility
XOMAP is the less volatile stock with a 0.13 beta — it tends to amplify market swings less than VRTX's 0.44 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. VRTX currently trades 92.0% from its 52-week high vs XOMAP's 85.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | XOMAPXOMA Corporation | VRTXVertex Pharmaceut… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.13x | 0.44x |
| 52-Week HighHighest price in past year | $30.00 | $519.68 |
| 52-Week LowLowest price in past year | $24.96 | $362.50 |
| % of 52W HighCurrent price vs 52-week peak | +85.9% | +92.0% |
| RSI (14)Momentum oscillator 0–100 | 38.3 | 50.0 |
| Avg Volume (50D)Average daily shares traded | 991 | 1.4M |
Analyst Outlook
Wall Street rates XOMAP as "Buy" and VRTX as "Buy". XOMAP is the only dividend payer here at 1.81% yield — a key consideration for income-focused portfolios.
| Metric | XOMAPXOMA Corporation | VRTXVertex Pharmaceut… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | — | $545.08 |
| # AnalystsCovering analysts | 9 | 55 |
| Dividend YieldAnnual dividend ÷ price | +1.8% | — |
| Dividend StreakConsecutive years of raises | 0 | — |
| Dividend / ShareAnnual DPS | $0.47 | — |
| Buyback YieldShare repurchases ÷ mkt cap | +0.0% | +1.7% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Dec 20 | Mar 26 | Change |
|---|---|---|---|
| XOMA Corporation (XOMAP) | 100 | 105.49 | +5.5% |
| Vertex Pharmaceutic… (VRTX) | 100 | 211.84 | +111.8% |
Vertex Pharmaceutic… (VRTX) returned +125% over 5 years vs XOMA Corporation (XOMAP)'s +46%. A $10,000 investment in VRTX 5 years ago would be worth $22,544 today (including dividends reinvested).
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| XOMA Corporation (XOMAP) | $6M | $28M | +412.0% |
| Vertex Pharmaceutic… (VRTX) | $1.7B | $12.0B | +605.1% |
Vertex Pharmaceuticals Incorporated's revenue grew from $1.7B (2016) to $12.0B (2025) — a 24.2% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| XOMA Corporation (XOMAP) | -9.6% | -48.5% | -404.3% |
| Vertex Pharmaceutic… (VRTX) | -6.6% | 32.9% | +600.4% |
Vertex Pharmaceuticals Incorporated's net margin went from -7% (2016) to 33% (2025).
Chart 4P/E Ratio History — 8 Years
| Stock | 2017 | 2025 | Change |
|---|---|---|---|
| Vertex Pharmaceutic… (VRTX) | 144.1 | 29.6 | -79.5% |
Vertex Pharmaceuticals Incorporated has traded in a 21x–144x P/E range over 8 years; current trailing P/E is ~31x.
Chart 5EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| XOMA Corporation (XOMAP) | -4.72 | -1.65 | +65.0% |
| Vertex Pharmaceutic… (VRTX) | -0.46 | 15.32 | +3430.4% |
Vertex Pharmaceuticals Incorporated's EPS grew from $-0.46 (2016) to $15.32 (2025).
Chart 6Free Cash Flow — 5 Years
XOMA Corporation generated $-14M FCF in 2024 (-260% vs 2021). Vertex Pharmaceuticals Incorporated generated $3B FCF in 2025 (+33% vs 2021).
XOMAP vs VRTX: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is XOMAP or VRTX a better buy right now?
Vertex Pharmaceuticals Incorporated (VRTX) offers the better valuation at 31.2x trailing P/E (24.7x forward), making it the more compelling value choice. Analysts rate XOMA Corporation (XOMAP) a "Buy" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — XOMAP or VRTX?
On forward P/E, Vertex Pharmaceuticals Incorporated is actually cheaper at 24.7x.
03Which is the better long-term investment — XOMAP or VRTX?
Over the past 5 years, Vertex Pharmaceuticals Incorporated (VRTX) delivered a total return of +125.4%, compared to +45.9% for XOMA Corporation (XOMAP). A $10,000 investment in VRTX five years ago would be worth approximately $23K today (assuming dividends reinvested). Over 10 years, the gap is even starker: VRTX returned +425.4% versus XOMAP's +50.5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — XOMAP or VRTX?
By beta (market sensitivity over 5 years), XOMA Corporation (XOMAP) is the lower-risk stock at 0.13β versus Vertex Pharmaceuticals Incorporated's 0.44β — meaning VRTX is approximately 232% more volatile than XOMAP relative to the S&P 500. On balance sheet safety, Vertex Pharmaceuticals Incorporated (VRTX) carries a lower debt/equity ratio of 20% versus 146% for XOMA Corporation — giving it more financial flexibility in a downturn.
05Which has better profit margins — XOMAP or VRTX?
Vertex Pharmaceuticals Incorporated (VRTX) is the more profitable company, earning 32.9% net margin versus -48.5% for XOMA Corporation — meaning it keeps 32.9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: VRTX leads at 39.1% versus -140.3% for XOMAP. At the gross margin level — before operating expenses — XOMAP leads at 99.3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is XOMAP or VRTX more undervalued right now?
On forward earnings alone, Vertex Pharmaceuticals Incorporated (VRTX) trades at 24.7x forward P/E versus 38.7x for XOMA Corporation — 14.0x cheaper on a one-year earnings basis.
07Which pays a better dividend — XOMAP or VRTX?
In this comparison, XOMAP (1.8% yield) pays a dividend. VRTX does not pay a meaningful dividend and should not be held primarily for income.
08Is XOMAP or VRTX better for a retirement portfolio?
For long-horizon retirement investors, XOMA Corporation (XOMAP) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.13), 1.8% yield). Both have compounded well over 10 years (XOMAP: +50.5%, VRTX: +425.4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between XOMAP and VRTX?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. XOMAP pays a dividend while VRTX does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.